ArticleAmerican journal of hematology2015

Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis.

Nicole Randall et al.PubMed ↗Publisher ↗

No numbers read from the abstract.